Histological Changes in Kidney and Liver of Rats Due to Gold (III) Compound [Au(en)Cl2]Cl

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Ahmed, Ayesha ^a   Al Tamimi, Dalal M ^a   Isab, Anvarhusein A ^b   Alkhawajah, Abdulaziz M Mansour ^a   Shawarby, Mohamed A ^a  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^b KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

[DICHLORO(ETHYLENEDIAMINE)AURATE(III)]CHLORIDE; GOLD DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CONTROLLED STUDY; HEPATITIS; HISTOPATHOLOGY; KIDNEY TUBULE NECROSIS; LD 50; LIVER CONGESTION; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONHUMAN; PYELONEPHRITIS; RAT; TISSUE PRESERVATION;

ANIMALS; ANTINEOPLASTIC AGENTS; KIDNEY; LIVER; MALE; NECROSIS; ORGANOGOLD COMPOUNDS; RATS; RATS, WISTAR;

ANIMALIA; RATTUS;

EID: 84871656257     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051889     Document Type: Article

References (52)

1. Nagender RP, Eladia MP, Josef H, (2009) Gold and nano-gold in medicine: overview, toxicology and perspectives. J Appl Biomed 7(2): 75-91.
2. Pacheco EA, Tiekink E, Whitehouse MW (2009) Biomedical Applications of Gold and Gold Compounds. In: Cort C, Holliday R (Editors) Gold Science and Applications. World Gold Council, London, CRC Press 217-230.
3. Milacic V, Fregona D, Dou QP, (2008) Gold complexes as prospective metal-based anticancer drugs. Histol Histopathol 23(1): 101-8.
4. Kean WF, Forestier F, Kassam Y, Buchanan WW, Rooney PJ, (1985) The history of gold therapy in rheumatoid disease. Semin Arthritis Rheum 14(3): 180-6.
5. Mahdihassan S, (1985) Cinnabar-gold as the best alchemical drug of longevity, called Makaradhwaja in India. Am J Chin Med 13(1-4): 93-108.
6. Daniel MC, Astruc D, (2004) Gold Nanoparticles: assembly, supramolecular chemistry, quantum-size related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev 104(1): 293-346.
7. Kean WF, Gerecz E, Hogan MG, (1987) Gold therapy II. Historical, chemical, pharmacological and biological profile of anti-arthritic gold compounds. Singapore Med J 28(2): 117-25.
8. Felson DT, Anderson JJ, Meenan RF, (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two meta analyses. Arthritis Rheum 33(10): 1449-61.
9. Shaw IC, (1999) Gold-based therapeutic agents. Chem Rev 99(9): 2589-2600.
10. Bhattacharya R, Mukherjee P, (2008) Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev 60: 1289-1306.
11. Wu ML, Tsai WJ, Ger J, Deng JF, Tsay SH, et al. (2001) Cholestatic hepatitis caused by acute gold potassium cyanide poisoning. Clin Toxicol 39: 739-43.
12. Cattaruzza L, Fregona D, Mongiat M, Ronconi L, Fassina A, et al. (2011) Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts. Int J Cancer 128(1): 206-15.
13. Rosenberg B, VanCamp I, Krigas T, (1965) Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode. Nature 205: 698-9.
14. Rosenberg B, VanCamp I, Trosko JE, Mansour VH, (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222(5191): 385-6.
15. Galanski M, Jakupec MA, Keppler BK, (2005) Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches. Curr Med Chem 12(18): 2075-94.
16. Ott I, (2009) Review On the medicinal chemistry of gold complexes as anticancer drugs. Coord Chem Rev 253(11-12): 1670-81.
17. Schmidbauer H (1999) Gold-progress in chemistry, biochemistry and technology. Chichester, John Wiley & Sons.
18. Hoke GD, Macia RA, Meunier PC, Bugelski PJ, Mirabelli CK, et al. (1989) In vivo and in vitro cardiotoxicity of a gold containing antineoplastic drug candidate in the rabbit. Toxicol Appl Pharmacol 100(2): 293-306.
19. Tiekink ER, (2002) Gold derivatives for the treatment of cancer. Crit Rev Oncol Hematol 42: 225-48.
20. Kelland L, (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-84.
21. Meijer S, Mulder NH, Sleijfer DT, de Jong PE, Sluiter WJ, et al. (1982) Nephrotoxicity of cis-diamminedichloride platinum [CDDP] during remissioninduction and maintenance chemotherapy of the testicular carcinoma. Cancer Chemother Pharmacol 8: 27-30.
22. Brock PR, Koliouska DE, Baratt TM, Yeomans E, Pritchard J, (1991) Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 118: 531-4.
23. Chao S, Chiang J, Huang A, Chang W, (2011) An integrative approach to identifying cancer chemoresistance-associated pathways. BMC Medical Genomics 4(1): 23-37.
24. Yamashita T, Miyamoto S, O'Malley B, Li D, (2010) The Role of PARP 1 for Cisplatin-Based Chemoresistance. Otolaryngol Head Neck Surg 143(2): 54-60.
25. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, et al. (2010) Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes & Dev 24: 837-852.
26. Ott I, Gust R, (2007) Non Platinum Metal Complexes as Anti-cancer Drugs. Arch Pharm Chem Life Sci 340: 117-126.
27. Milovanović M, Djeković A, Volarević V, Petrović B, Arsenijević N, et al. (2010) Ligand substitution reactions and cytotoxic properties of [Au(L)Cl2]+ and [AuCl2(DMSO)2]+ complexes (L = ethylenediamine and S-methyl-l-cysteine). J Inorg Biochem 104(9): 944-9.
28. Al-Maythalony BA, Wazeer MIM, Isab AA, (2009) Synthesis and characterization of gold(III) complexes with alkyldiamine ligands. Inorg Chim Acta 362: 3109-13.
29. Zhu S, Gorski W, Powell DR, Walmsley JA, (2006) Synthesis, Structures, and Electrochemistry of Gold(III) Ethylenediamine Complexes and Interactions with Guanosine 5'-Monophosphate. Inorg. Chem 45 (6): 2688-94.
30. Miller LC, Tainter MI, (1937) Estimation of LD50 or ED50 values and their errors using Log-Probit graph paper. Proc Soc Expt. Biol. Med 57: 261-264.
31. Underwood JCE (1985) Histochemistry. Theoretical and applied. Vol. 2: Analytical technology Pearse AGE. Fourth edition. Churchill Livingstone, Edinburgh.
32. Zhang J, Brown RP, Shaw M, Vaidya VS, Zhou Y, et al. (2008) Immunolocalization of Kim-1, RPA-1, and RPA-2 in Kidney of Gentamicin-, Mercury-, or Chromium-treated Rats: Relationship to Renal Distributions of iNOS and Nitrotyrosine. Toxicol Pathol 36(3): 397-409.
33. Ramachandran R, Kakar S, (2009) Histological patterns in drug-induced liver disease. J Clin Pathol 62: 481-92.
34. Bindoli A, Rigobello MP, Scutari G, Gabbiani C, Casini A, et al. (2009) Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs. Coord Chem Rev 253(11-12): 1692-07.
35. Magherini F, Modesti A, Bini L, Puglia M, Landini I, et al. (2010) Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. J Biol Inorg Chem 15(4): 573-82.
36. Chow KH, Sun RW, Lam JB, Li CK, Xu A, et al. (2010) A gold(III) porphyrin complex with antitumor properties targets the Wnt/beta-catenin pathway. Cancer Res 70(1): 329-37.
37. Yan JJ, Chow AL, Leung CH, Sun RW, Ma DL, et al. (2010) Cyclometalated gold(III) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons. Chem Commun (Camb) 46(22): 3893-5.
38. Hanigan MH, Lykissa ED, Townsend DM, Ou C, Barrios R, et al. (2010) γ-Glutamyl Transpeptidase-Deficient Mice Are Resistant to the Nephrotoxic Effects of Cisplatin. Am J Pathol 159(5): 1889-94.
39. Atasayara S, Gürer-Orhanb H, Orhanb H, Gürelc B, Girgina G, et al. (2009) Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats. Exp Toxicol Pathol 61(1): 23-32.
40. Ravindra P, Bhiwagade DA, Kulkarni S, Rataboli PV, Dhume CY, (2010) Cisplatin induced histological changes in renal tissue of rat. J Cell Animal Bio 4(7): 108-11.
41. Grönroos M, Chen M, Jahnukainen T, Capitanio A, Aizman RI, et al. (2006) Methotrexate induces cell swelling and necrosis in renal tubular cells. Pediatr Blood Cancer 1 46(5): 624-9.
42. Rollino C, Beltrame G, Ferro M, Quattrocchio G, Tonda L, et al. (2010) Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors. G ItalNefrol 50: S70-4.
43. Healy E, Dempsey M, Lally C, Ryan MP, (1998) Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int 54(6): 1955-66.
44. Yao X, Panichpisal K, Kurtzman N, Nugent K, (2007) Cisplatin Nephrotoxicity: A Review: oxygen species. Am J Med Sci 334(2): 115-24.
45. Arany I, Safirstein RL, (2010) Cisplatin nephrotoxicity. Semin Nephrol 2003 23: 460-4.
46. Basu A, Krishnamurthy S (2010) Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids. doi:10.4061/2010/201367.
47. Isab AA, Sheikh MN, Monim-ul-Mehboob M, Al-Maythalony BA, Wazeer MIM, (2011) Synthesis, characterization and anti proliferative effect of [Au(en)2]Cl3 and [Au(N-propyl-en)2]Cl3 on human cancer cell lines: Spectrochimica acta Part A Molecular and biomolecular spectroscopy. 79(5): 1196-1201.
48. Avci A, Cetin R, Erguder IB, Devrim E, Kilicoglu B, et al. (2008) Cisplatin Causes Oxidation in Rat Liver Tissues:Possible Protective Effects of Antioxidant Food Supplementation. Turk J Med Sci 38 (2): 117-120.
49. Liu J, Liu Y, Habeebu SS, Klaassen CD, (1998) Metallothionein (MT)-null mice are sensitive to cisplatin-induced hepatotoxicity. Toxicol Appl Pharmacol 149: 24-31.
50. Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC, (2008) Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol 28(3): 337-44.
51. El-Sayyad HI, Ismail MF, Shalaby FM, Abou-El-Magd RF, Gaur RL, et al. (2009) Histopathological effects of cisplatin, doxorubicin and5-flurouracil (5-FU) on the liver of male albino rats. Int J Biol Sci 28 5(5): 466-73.
52. Kart A, Cigremis Y, Karaman M, Ozen H, (2010) Caffeic acid phenethyl ester (CAPE) ameliorates cisplatin-induced hepatotoxicity in rabbit. Exp Toxicol Pathol 62(1): 45-52.